Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk

Ann Neurol. 2016 Nov;80(5):791. doi: 10.1002/ana.24768. Epub 2016 Sep 15.

Authors

Romain Marignier^{1

2

3

4}, Françoise Durand-Dubief¹, Renaud du Pasquier⁵, Sandra Vukusic^{1

2

3

4}

Affiliations

¹ Neurology A, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon, France.
² Neuro-oncology and Neuroinflammation Team, Lyon Neurosciences Research Center, Lyon, France.
³ Claude Bernard University Lyon 1, Lyon, France.
⁴ University of Lyon, Lyon, France.
⁵ Laboratory of Neuroimmunology, Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland.

PMID: 27554031
DOI: 10.1002/ana.24768

No abstract available

Publication types

Letter
Comment

MeSH terms

Fingolimod Hydrochloride
Humans
Immunologic Factors
Leukoencephalopathy, Progressive Multifocal*
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Natalizumab*
Rituximab

Substances

Immunologic Factors
Natalizumab
Rituximab
Fingolimod Hydrochloride